Adherence,Persistence,and Predictors Associated with Early Niacin Termination

Abstract

Background:

Niacin is the most effective therapy currently available to increase high-density lipoprotein cholesterol. However, adherence to niacin may be limited by a number of factors and it is important to characterize who is likely to discontinue the medicine.

Objective:

To measure adherence and persistence to niacin, estimate the influence of niacin dose on adherence, and identify factors associated with early termination of niacin.

Methods:

This retrospective study estimated adherence to niacin by calculating the medication possession ratio, persistence, number of refills, and termination proportion in a large, deidentified US health claims database consisting of 42,685 insurance-carrying adults who were new users of niacin.

Results:

We identified 29,801 new users of niacin who were not taking statins or fibric acid, 12,298 new users of niacin plus statin, 441 new users of niacin plus fibric acid, and 145 new users who initiated all 3 agents. Persistence was lowest among individuals taking less than 1 g/day and was highest among those taking niacin plus fibric acid plus statin (5.10 vs 7.17 months, respectively). However, lower niacin dose was associated with greater adherence, regardless of statin use. Termination of niacin within 1 year of initiation was significantly associated with being female or having 1 of the following conditions: peripheral vascular disease, chronic pulmonary disease, diabetes mellitus, rheumatic disease, or liver disease. Increased age, taking niacin in combination with a statin, or taking drugs from 2 or more concomitant prescription medication classes were significantly associated with a reduced likelihood of termination within 1 year.

Conclusions:

We observed relatively high adherence rates to niacin; however, most patients failed to persist with use of the drug beyond 7 months.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Deaths and mortality. Hyattsville, MD: CDC, 2010. www.cdc.gov/heartdisease/facts.htm (accessed 2011 Mar 22).

World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization, 2009.

Smith

Jr Allen

Blair

. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363–72.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.

Christian

Bourgeois

Snipes

Lowe

. Prevalence of severe (500 to 2,000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol 2011; 107: 891–7.

Ford

Zhao

Pearson

Mokdad

. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169: 572–8.

Brown

Zhao

Chait

. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–92.

Cheung

Zhao

Chait

Albers

Brown

. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001; 21: 1320–6.

Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–81.

10.

Guyton

. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998; 82: 18U–23U; discussion 39U–41U.

11.

Berge

Canner

. Coronary drug project: Experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40 (suppl 1): S49–51.

12.

Vosper

. Niacin: A re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158: 429–41.

13.

Capuzzi

Guyton

Morgan

. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 1998; 82: 74U–81U; discussion 5U–6U.

14.

Carlson

Hamsten

Asplund

. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 1989; 226: 271–6.

15.

Guyton

Blazing

Hagar

. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160: 1177–84.

16.

Guyton

Goldberg

Kreisberg

Sprecher

Superko

O'Connor

. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hyper-cholesterolemia. Am J Cardiol 1998; 82: 737–43.

17.

Knopp

Alagona

Davidson

. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097–104.

18.

Barter

Caulfield

Eriksson

. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–22.

19.

Ginsberg

Elam

Lovato

. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–74.

20.

ClinicalTrials.gov. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE (NCT00461630) 2010. http://clinicaltrials.gov/show/NCT00461630 (accessed 2013 Jun 6).

21.

Boden

Probstfield

Anderson

. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255–67.

22.

Cramer

Roy

Burrell

. Medication compliance and persistence: Terminology and definitions. Value Health 2008; 11: 44–7.

23.

Aubert

Yao

Xia

Garavaglia

. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care 2010; 16: 459–66.

24.

Kamanna

Ganji

Kashyap

. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009; 63: 1369–77.

25.

Charlson

Pompei

Ales

MacKenzie

. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373–83.

26.

IMS. The Uniform System of Classification (USC), 2008. www.imshealth.com/deployedfiles/ims/Global/Content/Insights/Health%20Services%20Research%20Network/USC_Classification_Process_2011.pdf (accessed 2011 Mar 22).

27.

World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization, 2003. www.who.int/chp/knowledge/publications/adherence_report/en (accessed 2011 Mar 22).

28.

Jacobson

. A “hot” topic in dyslipidemia management— “how to beat a flush”: Optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc 2010; 85: 365–79.

29.

Avorn

Monette

Lacour

. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998; 279: 1458–62.

30.

Benner

Glynn

Mogun

Neumann

Weinstein

Avorn

. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61.

31.

Vinker

Shani

Baevsky

Elhayany

. Adherence with statins over 8 years in a usual care setting. Am J Manag Care 2008; 14: 388–92.

32.

Andrade

Walker

Gottlieb

. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125–31.

33.

LaFleur

Thompson

Joish

Charland

Oderda

Brixner

. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006; 40: 1274–9. doi: 10.1345/aph.1G646

34.

Elliott

. Optimizing medication adherence in older persons with hypertension. Int Urol Nephrol 2003; 35: 557–62.

35.

Balu

Simko

Quimbo

Cziraky

. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009; 25: 2765–75.

36.

Curtis

Westfall

. Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis. Med Care 2009; 47: 334–41.

37.

Weart

Hogan

. Event reduction: Revisiting why we treat with statins and harnessing current evidence towards optimal therapy. Exp Opin Pharmacother 2011; 12: 99–117.

38.

Benner

Tierce

Ballantyne

. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 (suppl 3): 13–23.

39.

Brookhart

Patrick

Schneeweiss

. Physician follow-up and provider continuity are associated with long-term medication adherence: A study of the dynamics of statin use. Arch Intern Med 2007; 167: 847–52.